Sarepta TherapeuticsSRPT
SRPT
$128.92
3.63%
Market Cap: $12.2B
0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 25 analysts
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
145% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 49
100% more call options, than puts
Call options by funds: $650M | Put options by funds: $325M
41% more repeat investments, than reductions
Existing positions increased: 178 | Existing positions reduced: 126
30% more capital invested
Capital invested by funds: $10.7B [Q1] → $13.9B (+$3.25B) [Q2]
17% more funds holding
Funds holding: 407 [Q1] → 478 (+71) [Q2]
7% more funds holding in top 10
Funds holding in top 10: 15 [Q1] → 16 (+1) [Q2]
5.3% more ownership
Funds ownership: 88.08% [Q1] → 93.37% (+5.3%) [Q2]
Research analyst outlook
25 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$128
1%
downside
Avg. target
$186
45%
upside
High target
$235
82%
upside
25 analyst ratings
19 positive
76%
6 neutral
24%
0 negative
0%
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 40%upside $181 | Outperform Reiterated | 6 Sept 2024 |
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 40%upside $181 | Outperform Reiterated | 15 Aug 2024 |
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target | 40%upside $181 | Outperform Maintained | 8 Aug 2024 |
Citigroup David Hoang 67% 1-year accuracy 14 / 21 met price target | 24%upside $160 | Neutral Maintained | 8 Aug 2024 |
Cantor Fitzgerald Kristen Kluska 59% 1-year accuracy 48 / 81 met price target | 18%upside $152 | Neutral Maintained | 8 Aug 2024 |
Financial journalist opinion
Based on 8 articles about SRPT published over the past 30 days